Ornge Transport Medicine, Mississauga, ON.
Division of Emergency Medicine, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON.
CJEM. 2020 Sep;22(S2):S67-S73. doi: 10.1017/cem.2020.2.
Early administration of blood products to patients with hemorrhagic shock has a positive impact on morbidity and mortality. Smaller hospitals may have limited supply of blood, and air medical systems may not carry blood. The primary outcome is to quantify the number of patients meeting established physiologic criteria for blood product administration and to identify which patients receive and which ones do not receive it due to lack of availability locally.
Electronic patient care records were used to identify a retrospective cohort of patients undergoing emergent air medical transport in Ontario, Canada, who are likely to require blood. Presenting problems for blood product administration were identified. Physiologic data were extracted with criteria for transfusion used to identify patients where blood product administration is indicated.
There were 11,520 emergent patient transports during the study period, with 842 (7.3%) where blood product administration was considered. Of these, 290 met established physiologic criteria for blood products, with 167 receiving blood, of which 57 received it at a hospital with a limited supply. The mean number of units administered per patient was 3.5. The remaining 123 patients meeting criteria did not receive product because none was unavailable.
Indications for blood product administration are present in 2.5% of patients undergoing time-sensitive air medical transport. Air medical services can enhance access to potentially lifesaving therapy in patients with hemorrhagic shock by carrying blood products, as blood may be unavailable or in limited supply locally in the majority of patients where it is indicated.
对出血性休克患者进行早期血制品治疗对发病率和死亡率有积极影响。小医院的血源可能有限,空中医疗系统可能不携带血液。主要结果是量化符合血制品治疗既定生理标准的患者人数,并确定由于当地无法获得血源而接受和不接受治疗的患者。
使用电子患者护理记录来确定加拿大安大略省进行紧急空中医疗转运的回顾性队列患者,这些患者可能需要血液。确定了血制品治疗的提出问题。提取生理数据,并使用输血标准来确定需要血制品治疗的患者。
在研究期间进行了 11520 次紧急患者转运,其中 842 次(7.3%)考虑进行血制品治疗。其中,290 名患者符合既定的血制品生理标准,其中 167 名接受了血液,其中 57 名在血源有限的医院接受了治疗。每位患者接受的平均单位数为 3.5。其余 123 名符合标准的患者未接受治疗,因为均无血源。
在进行时间敏感的空中医疗转运的患者中,有 2.5%符合血制品治疗的适应证。空中医疗服务可以通过携带血制品来增加对出血性休克患者潜在救生治疗的可及性,因为在大多数需要治疗的患者中,血源可能无法获得或当地供应有限。